Support Psychable's Journey. Contribute Here.

While Suicide Remains A Leading Cause Of Death In The U.S., Depression Treatment Options Expand as Psychedelic-Assisted Therapy Proves to be an Increasingly Effective Approach to Transformative Mental Health

This Suicide Prevention Week, Psychable Offers Comprehensive Information on Treatment Options and Safe Access to Practitioners Through Supportive Online Community


LOS ANGELES, Sept. 06, 2021 (GLOBE NEWSWIRE) — National Suicide Prevention Week shines a light on the widespread mental health issue that affects all communities, the medical, socioeconomic and genetic factors that contribute to suicide and depression, as well as the treatment options that are increasingly available to those looking for help. The second leading cause of death among individuals between the ages of 10 and 34, it’s impossible to observe National Suicide Prevention Week without talking about depression – a primary contributor to the cause of suicide. In recent years, the use of psychedelic-assisted therapy to treat depression has increased which, in turn, has resulted in more inquiries about the treatment. Psychable is the #1 most trusted and comprehensive online community dedicated to connecting those interested in legally exploring psychedelic-assisted therapy with practitioners in the space.

Psychedelic-assisted therapy is the use of psychedelics for healing purposes, often taking the form of a psychedelic being administered under the supervision of a therapist. In recent years, ketamine and the innovation of its use for treating different forms of depression has become increasingly more interesting as it is evident that it can provide rapid relief to persons with treatment-resistant depression. The treatment is now offered in therapeutic settings via a variety of administration routes, including infusion, intramuscular injection, intranasally, by mouth, and even sublingually.

Recent studies have shown psychedelic-assisted therapy can have long-lasting, fast-acting, and impactful results when it comes to treating those suffering with depression, trauma and addiction. When administered under the supervision of or with the aftercare of a therapist, evidence shows that substances such as ketamine, MDMA, and psilocybin are successful at reducing fear and defensiveness, enhancing introspection and breaking traumatic thought patterns to provide rapid and lasting relief.

Psychable is committed to connecting those interested in legally exploring psychedelic-assisted therapy as a treatment for depression with practitioners in the space. Candidates looking for treatment and practitioners will find support for every stage of the psychedelic journey through the Psychable community at

“The silent suicide pandemic is an issue that requires everyone’s full attention and support, including medical professionals, social workers, friends and family members. Psychable is dedicated to doing our part by providing information on legal psychedelic-assisted therapy treatment options, as well as access to community-reviewed practitioners, for those seeking treatment. It’s our hope that candidates interested in this alternative wellness approach find the healing they need,” said Jemie Sae Koo, Co-Founder and CEO of Psychable.

Psychable was founded by serial entrepreneurs Jemie Sae Koo and Matt Zemon, a pair united in a belief that psychedelics can provide meaningful and transformative treatments for not only those struggling with a myriad of ailments, but also those looking to transform their lives for the better. With both having transformative experiences with psychedelic medicine that led them to pursuing a Master of Science Degree in Psychology with a focus on Psychedelic-Assisted Therapy, they’ve curated a team of experts with deep experience to lead the Psychable community to support all phases of the journey from information to integration.

Psychable is the holistic solution to connect psychedelic-assisted therapy practitioners with candidates seeking services. The platform streamlines the research period for candidates by offering filters for search including geolocation, treatment type, training or credentials, and other preferences to match with practitioners of their choosing. A true one-stop community for discovering and booking psychedelic-assisted treatments, Psychable’s network allows practitioners and patients to communicate directly with one another to discuss the best possible treatment plans and allows users to share recommendations and reviews of practitioners. Psychable also hosts an extensive library of proprietary, medically reviewed articles on all aspects of psychedelics as part of its mission to continue to inform and educate the world about the power of psychedelics as part of holistic health.

Psychable is open to all those who seek information on psychedelic-assisted therapy and practitioners who can help. For more information, to create your profile or secure your listing, please visit Follow along via social media on LinkedinInstagramTwitter, and Facebook.

About Psychable
Psychable is the #1 most trusted and comprehensive online community connecting those who would like to legally explore the healing power of psychedelics with medically and peer-reviewed practitioners. The community offers support for those seeking information, current patients and practitioners wherever they are in their journey with psychedelic-assisted therapy. Our mission is to transform the lives of millions of people suffering with conditions such as depression, PTSD and addiction by connecting them to psychedelic-based treatments, including integration, psychedelic-assisted therapy and retreats. Psychable was launched in 2021 by Jemie Sae Koo and Matt Zemon, successful entrepreneurs whose transformative experiences with psychedelic medicine led them to each pursue a Master of Science Degree in Psychology with a focus on Psychedelic-Assisted Therapy. The platform is supported by a passionate team of experts in psychology, business, medicine, and law. For more information on our mission and community, visit, or follow us on LinkedinInstagramTwitter, and Facebook.


Share This Article